

PATENT
Customer No. 22,852
Attorney Docket No. 06478.1457-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)

Juergen ROEMISCH, et al.)

Application No.: 09/912,559)

Filed: July 26, 2001)

For: MUTANTS OF THE FACTOR VII-)
ACTIVATING PROTEASE AND)
DETECTION METHODS USING)
SPECIFIC ANTIBODIES)

Group Art Unit: 1652

Examiner: Elizabeth Slobodyansky

RECEIVED

SEP 12 2003

TECH CENTER 1600/2900

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Office the documents listed on the attached PTO form 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed documents, including any copending patent applications, are attached.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP
1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

09/11/2003 CCHAU1

00000113 09912559

02 FC:1806

180.00 DP

In lieu of a statement of relevance for EP 1 059 359 A2, its relevance may be found in US2003/0124622A1, which is an English-language family member of the European application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Office applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, that is not submitted herewith please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 10, 2003

By: 
Elizabeth A. Doherty
Reg. No. 50,894

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06478.1457-00	Appln. No.	09/912,559
Applicant	Juergen ROEMISCH, et al.		
Filing Date	July 26, 2001	Group:	1652

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Publication Date	Name	Class	Sub Class	Filing Date If Applicable
1	US2003/0124622A1	July 3, 2003	ROEMISCH et al.	435	7.4	

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
2	EP 1 059 359 A2	December 13, 2000	EPO	C12Q	1/37 no

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

3	J. Römisch et al., "Quantitation of the Factor VII- and Single Chain Plasminogen Activator-Activating Protease in Plasmas of Healthy Subjects," <i>Blood Coagulation and Fibrinolysis</i> , 12(5):375-383 (2001).
4	N.-H. Choi-Miura et al., "Purification and Characterization of a Novel Hyaluronan-Binding Protein (PHBP) from Human Plasma: It Has Three EGF, a Kringle and a Serine Protease Domain, Similar to Hepatocyte Growth Factor Activator," <i>J. Biochem.</i> , 119(6):1157-1165 (1996).
5	N.-H. Choi-Miura et al., "Proteolytic Activation and Inactivation of the Serine Protease Activity of Plasma Hyaluronan Binding Protein," <i>Biol. Pharm. Bull.</i> , 24(5):448-452 (2001).
6	J. Römisch et al., "A Protease Isolated from Human Plasma Activating Factor VII Independent of Tissue Factor," <i>Blood Coagulation and Fibrinolysis</i> , 10(8):471-479 (1999).
7	J. Römisch et al., "The FVII Activating Protease Cleaves Single-Chain Plasminogen Activators," <i>Haemostasis</i> , 29(5):292-299 (1999).
8	J. Willeit et al., "Marburg I Polymorphism of Factor VII-Activating Protease: A Prominent Risk Predictor of Carotid Stenosis," <i>Circulation</i> , 107(5):667-670 (2003).
9	J. Römisch "Factor VII Activating Protease (FSAP): A Novel Protease in Hemostasis," <i>Biol. Chem.</i> , 383:1119-1124 (2002).
10	J. Römisch et al., "The Frequent <i>Marburg I</i> Polymorphism Impairs the Pro-Urokinase Activating Potency of the Factor VII Activating Protease (FSAP)," <i>Blood Coagulation and Fibrinolysis</i> , 13(5):433-441 (2002).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce